Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- eBayeBay publishes 2025 Impact ReportCompanies: eBayThe report showcases how our people, platform, and community are expanding opportunity, reducing waste, and building an inclusive future.
- Hyundai Motor CompanyHyundai Motor Group’s Mobile Robot Platform ‘MobED’ Honored as ‘Winner’ at 2026 Red Dot Design AwardCompanies: Hyundai Motor CompanyHyundai Motor Group Robotics LAB’s mobile robot platform MobED named a ‘Winner’ at the 2026 Red Dot Award showcasing innovative design and real-world usability Embodies design rooted in the Robotics LAB ‘Refined Edge’ philosophy, which focuses on enhancing human-centered interaction and real-world usability Showcases a scalable platform combining advanced engineering, AI control and human-centered design
- TikTokBuilt on TikTok: Celebrating the Thriving Small Business CommunityCompanies: ByteDanceTikTok is where people turn ideas into successful businesses by tapping into a highly engaged community of more than 1 billion users globally. For many small businesses, the platform creates an opportunity to build loyal customers, grow their brands, and transform their futures through the success they find on TikTok.In celebration of Small Business Month this May, we hosted Built on TikTok: Small Business Showcase, to spotlight incredible brands and creators who are building successful businesses through TikTok.…
- Hyundai Motor CompanyHyundai Motor Group Expands Pan-India Network to Accelerate Battery and Electrification ResearchCompanies: Hyundai Motor CompanyHyundai Motor Group expands its Hyundai Center of Excellence (Hyundai CoE) to seven universities through four additional partnerships The expanded joint platform, India’s premier academic-industrial network for battery and electrification research, builds on the initial 2025 launch The platform is advancing 39 joint research projects through the Hyundai CoE network The initiative leverages these academic partnerships to establish a robust research ecosystem that accelerates India's electrification journey
- TikTokTikTok and FIFA Introduce the FIFA World Cup 2026™ Creator CorrespondentsCompanies: ByteDanceThirty global TikTok creators will deliver behind-the-scenes access, live perspectives, and fan-led storytelling throughout the FIFA World Cup 2026™TikTok and FIFA today announced the FIFA World Cup 2026™ Creator Correspondents — a globally representative cohort of 30 TikTok creators who will capture the tournament through creator-led, fan-first storytelling. The program builds on TikTok and FIFA's Preferred Platform agreement to expand audience reach, promote live match discovery, and create greater opportunities…
- OracleOracle Named a Leader in Gartner® Magic Quadrant™ for Warehouse Management Systems for 11th Consecutive YearCompanies: Oracle CorporationOracle has been named a Leader in the 2026 Gartner® Magic Quadrant™ for Warehouse Management Systems. The report evaluated Oracle Fusion Cloud...
- OpenAIAdvancing voice intelligence with new models in the APICompanies: OpenAIExplore new realtime voice models in the OpenAI API that can reason, translate, and transcribe speech, enabling more natural and intelligent voice experiences.
- BayerBayer to acquire Perfuse Therapeutics to complement ophthalmology pipelineCompanies: BayerBayer and Perfuse Therapeutics Inc. today announced an agreement under which Bayer will fully acquire Perfuse Therapeutics, a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. With this acquisition, Bayer will hold the full rights pertaining to PER-001, a small molecule endothelin receptor antagonist currently in Phase II clinical development for the treatment of Glaucoma and Diabetic Retinopathy (DR). This represents one of the first potential treatments for Glaucoma and DR being studied for its ability to improve the visual field for Glaucoma patients and to improve contrast sensitivity and reduce ischemia in DR patients. “We are excited by the work of the team at Perfuse Therapeutics and encouraged by the potential of PER-001,” said Juergen Eckhardt, M.D., Head of Business Development and Licensing at Bayer Pharmaceuticals. “With this acquisition, we are complementing our expertise in ophthalmology and our pipeline, reinforcing our commitment to developing urgently needed therapies for patients.” “I’m incredibly proud of what the Perfuse team has accomplished and deeply thankful to all our investors and collaborators," said Sevgi Gurkan, MD, Founder and CEO of Perfuse Therapeutics, Inc. "Bayer’s vision aligns closely with ours, and they have the scale and global resources to unlock the full potential of PER-001 to change the trajectory of human blindness. We are very excited to see our mission continue with even greater momentum.” Glaucoma is a progressive optic neuropathy that causes the loss of retinal ganglion cells, resulting in loss of visual fields. It is the leading cause of irreversible vision loss1 affecting ~76-80 million people worldwide (2020) and is projected to affect ~112 million people by 2040 due to population aging.2 Despite its prevalence, there are no approved treatments today, preventing disease progression and blindness independently from the saturated approach of lowering intraocular pressure. There is a high unmet medical need for neuroprotective treatments for patients with Glaucoma. Diabetic Retinopathy (DR) is a microvascular complication of diabetes that damages retinal capillaries, causing ischemia, leakage, and neovascularization affecting about 146 million people globally today. This includes about 25 percent of adults with diabetes and is projected to increase to 160 million people by 2045. Currently, 25 million people have vision‑threatening DR and 1.3 million people are blind.3 Under the terms of the agreement, the transaction carries a total potential value of up to USD 2.45 billion, comprising a USD 300 million upfront payment and additional development, regulatory, and commercial milestone payments based on success criteria. For Bayer, BofA Securities is acting as exclusive financial advisor and Baker McKenzie is acting as legal counsel. For Perfuse, Centerview Partners LLC is acting as exclusive financial advisor and Goodwin Procter LLP is acting as legal counsel. The acquisition is subject to and will become effective after receiving the necessary antitrust clearances and Perfuse stockholder approvals. About PER-001 PER-001 is an investigational small molecule endothelin receptor antagonist being developed for the treatment of ophthalmic diseases. Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma, diabetic retinopathy, age-related macular degeneration and retinal vein occlusion. Endothelin is involved in inflammation and cell death through its receptors expressed in retinal vascular and neuroretinal cells. The PER-001 intravitreal implant is a bio-erodible implant administered into the vitreous cavity of the eye using a single-use, 25-gauge applicator and designed to provide a sustained release of PER-001, allowing for a convenient dosing regimen. About Perfuse Therapeutics Perfuse Therapeutics is a biopharmaceutical company pioneering transformational research into the treatment of ischemia-induced ocular diseases. Enabled by its proprietary sustained-release drug delivery platform, the company is advancing its lead asset PER-001 for global leading causes of blindness. Headquartered in South San Francisco, Calif., and with R&D facilities in Durham, N.C., Perfuse Therapeutics has established a strong team committed to advancing disease-modifying therapies to patients with ocular disease around the world. For more information, visit www.perfusetherapeutics.com and LinkedIn. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. 1 Vision Loss Expert Group of the Global Burden of Disease, 2024, Eye ² Sarkis et al., 2025, Frontiers in Med ³ WHO, 2019, World report on vision Executive Summary Bayer Global Media Contact: Lisa Varrelmann, phone +49 1746466492 Email: [email protected] Contact for investor inquiries: Bayer Investor Relations Team, phone +49 214 30-72704 Email: [email protected] www.bayer.com/de/investoren/ir-team Perfuse Therapeutics Media Contact: Perfuse Therapeutics Team Email: [email protected] Perfuse Therapeutics investor inquiries: Perfuse Therapeutics Team Email: [email protected]
- OracleIHH Healthcare Unifies Enterprise Systems with Oracle Fusion Cloud Applications to Strengthen Care Delivery Across MarketsCompanies: Oracle CorporationIHH Healthcare (IHH), one of the world's largest integrated healthcare providers, has selected Oracle Fusion Cloud Applications across its enterprise ...
- TikTokAsian and Pacific Islander Heritage Month 2026: Celebrating #APITikTokCompanies: ByteDanceFrom sharing family recipes to supporting API-owned small businesses, #APITikTok continues to shape culture through shared traditions and authentic community. This Asian and Pacific Islander Heritage Month, we're celebrating the achievements and impact of #APITikTok creators who inspire us on the For You Feed.#APITikTok SpotlightThe #APITikTok community continues to remind us that API identity is many things: joyful, powerful, creative, and never just one story. We're thrilled to shine a light on creators and smal…
- PepsiCoBOLD NEW LOOK, A BRIGHTER NEW MOOD: MIRINDA® LAUNCHES A "SMILE PLEASE" PLATFORM GLOBALLYCompanies: PepsiCoToday, Mirinda® has unveiled a powerful new global platform 'Smile Please' alongside a fresh brand visual identity. The fun and impactful movement is ...
- SASSAS AI Navigator to bring order to AI chaosNew SaaS platform will accept any model or agent, govern every use case and accelerate AI innovation The rush to implement AI leaves organizations struggling to track its use, with the promise of increased productivity leading to overreliance on unproven AI without sufficient trustworthy AI safeguards. To bring order to the chaos, SAS® AI Navigator will soon be available to help AI, data, compliance and risk leaders